![](/images/graphics-bg.png)
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
Joint Authors
Rolfo, Christian
Signorelli, Diego
Giannatempo, Patrizia
Grazia, Giulia
Aiello, Marco Maria
Bertolini, Federica
Mirabile, Aurora
Buti, Sebastiano
Vasile, Enrico
Pisapia, Pasquale
Cona, Maria Silvia
Group, Immune-Oncology YOUNG
Malapelle, Umberto
Scotti, Vieri
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-24
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy.
Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy.
However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need.
Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC).
Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression.
In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors.
In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.
American Psychological Association (APA)
Signorelli, Diego& Giannatempo, Patrizia& Grazia, Giulia& Aiello, Marco Maria& Bertolini, Federica& Mirabile, Aurora…[et al.]. 2019. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International،Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
Modern Language Association (MLA)
Signorelli, Diego…[et al.]. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International No. 2019 (2019), pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
American Medical Association (AMA)
Signorelli, Diego& Giannatempo, Patrizia& Grazia, Giulia& Aiello, Marco Maria& Bertolini, Federica& Mirabile, Aurora…[et al.]. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1128283